Market Cap : 423.86 M | Enterprise Value : 488.13 M | PE Ratio : At Loss | PB Ratio : |
---|
NAS:HLVX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:HLVX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
HilleVax's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $158.31 Mil. HilleVax's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $0.15 Mil. HilleVax's annualized EBITDA for the quarter that ended in Dec. 2021 was $-99.56 Mil. HilleVax's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 was -1.59.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for HilleVax's Debt-to-EBITDA or its related term are showing as below:
During the past 2 years, the highest Debt-to-EBITDA Ratio of HilleVax was -1.46. The lowest was -1.59. And the median was -1.53.
HLVX's Debt-to-EBITDA is ranked worse thanThe historical data trend for HilleVax's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HilleVax Semi-Annual Data | ||
Dec20 | Dec21 | |
Debt-to-EBITDA | -1.46 | -1.59 |
For the Biotechnology subindustry, HilleVax's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, HilleVax's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where HilleVax's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
HilleVax's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (158.308 | + | 0.153) | / | -99.561 | |
= | -1.59 |
HilleVax's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (158.308 | + | 0.153) | / | -99.561 | |
= | -1.59 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Dec. 2021) EBITDA data.
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of HilleVax's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Fhmls X, L.l.c. | 10 percent owner | 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 |
Dubin Gary | director | C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109 |
Borkowski Astrid | officer: Chief Medical Officer | C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109 |
Sepulveda Jaime | director | C/O HILLEVAX INC. 75 STATE STREET 100 - #9995 BOSTON MA 02109 |
Takeda Vaccines, Inc. | 10 percent owner | 75 SIDNEY STREET CAMBRIDGE MA 02139 |
Chu Shelley | director | ONE WINTHROP SQUARE SUITE 400 BOSTON MA 02110 |
Silbermann Susan Michele | director | C/O LIANBIO 103 CARNEGIE CENTER DRIVE, SUITE 215 PRINCETON NJ 08540 |
Fhmls X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 |
Frazier Life Sciences X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 |
Gerberding Julie L. | director | 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 |
Kohli Aditya | director, officer: Chief Operating Officer | C/O PHATHOM PHARMACEUTICALS, INC. 2150 E. LAKE COOK ROAD, SUITE 800 BUFFALO GROVE IL 60089 |
Socks David A | officer: CFO & Chief Business Officer | C/O CADENCE PHARMACEUTICALS, INC. 12481 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668 |
Hershberg Robert | director, officer: President and CEO | 3005 FIRST AVENUE SEATTLE WA 98121 |
Topper James N | 10 percent owner | 550 HAMILTON AVENUE, SUITE 100 PALO ALTO CA 94301 |
From GuruFocus
Other Sources
By tipranks.com 2022-05-25